Treatment of Melioidosis

Phase 1 - Intensive (Intravenous) Phase

• Development of organ failure
• New focus of infection appears
• Blood cultures remain positive after 1 week of treatment
• CNS involvement, deep-seated abscesses, extensive pulmonary disease, osteomyelitis, or septic arthritis

• Ongoing septic shock
• Deep-seated or organ abscesses
• Extensive pulmonary disease
• Osteomyelitis or septic arthritis
• Neurologic melioidosis (brainstem encephalitis, myelitis)
• Goldman-Cecil Medicine, p. 1168; Murray & Nadel's Respiratory Medicine, p. 1711; Andrews' Diseases of the Skin, p. 1025

Phase 2 - Eradication (Oral) Phase

• A 2023 systematic review (PMID: 37592339) confirmed the efficacy and safety of co-trimoxazole in the eradication phase, supporting its continued first-line role.
• Goldman-Cecil Medicine, p. 1168

Special Situations

Chronic/Cutaneous Melioidosis

• The majority of chronic cutaneous infections respond well to oral treatment alone (TMP-SMX), without the need for the IV intensive phase.
• Andrews' Diseases of the Skin, p. 1025

Neurological Melioidosis

• Meropenem is strongly preferred over ceftazidime due to better CNS penetration. IV therapy must continue for at least 4 weeks.

TMP-SMX Allergy or Intolerance

• Use amoxicillin-clavulanate (500 mg TID) as an oral alternative.
• In severe beta-lactam allergy during the IV phase, TMP-SMX IV can be considered.

Post-Exposure Prophylaxis

• After potential exposure (bioterrorism scenario - B. pseudomallei is a Category B bioterrorism agent): TMP-SMX or amoxicillin-clavulanate for 3 weeks in the same doses as eradication therapy.
• Goldman-Cecil Medicine, p. 1170

Antibiotic Resistance Notes

• B. pseudomallei is intrinsically resistant to the usual community-acquired pneumonia antibiotics (penicillin, ampicillin, first/second-generation cephalosporins, macrolides, and aminoglycosides as monotherapy).
• Sensitivity testing should guide therapy when available; strains vary particularly in susceptibility to TMP-SMX in certain regions.
• Murray & Nadel's Respiratory Medicine, p. 1711

Treatment Summary Table

Prognosis

Treatment of DTR Pseudomonas aeruginosa

What is DTR P. aeruginosa?

• All carbapenems (meropenem, imipenem, doripenem)
• All beta-lactam/beta-lactamase inhibitor combinations (piperacillin-tazobactam)
• All antipseudomonal cephalosporins (ceftazidime, cefepime)
• All fluoroquinolones (ciprofloxacin, levofloxacin)

Susceptibility of Novel Agents Against CRPA/DTR-PA

• Washington Manual of Medical Therapeutics, Table 15-1, p. 168

Treatment by Infection Site (IDSA 2024 Guidance)

1. Uncomplicated Cystitis

• Ceftolozane-tazobactam
• Ceftazidime-avibactam
• Imipenem-cilastatin-relebactam
• Cefiderocol
• Single-dose aminoglycoside (e.g., tobramycin once-daily)

2. Pyelonephritis / Complicated UTI (cUTI)

• Ceftolozane-tazobactam
• Ceftazidime-avibactam
• Imipenem-cilastatin-relebactam
• Cefiderocol

3. Non-Urinary Infections (Pneumonia, Bacteremia, Intra-abdominal, Skin/Soft Tissue)

• Ceftolozane-tazobactam
• Ceftazidime-avibactam
• Imipenem-cilastatin-relebactam

• Cefiderocol - used when the above are unavailable, resistant, or when MBL production is confirmed

Special Scenario: MBL-Producing DTR-PA (e.g., blaVIM, blaIMP, blaNDM)

• Cefiderocol - most active option (~99% susceptibility); preferred by IDSA
• Aztreonam-avibactam - limited data for MBL-PA; avibactam may help suppress PDC enzymes but multiple non-enzymatic resistance mechanisms in DTR-PA likely limit benefit
• Combination regimens under ID specialist guidance (e.g., colistin combinations as salvage)

Standard Dosing of Novel Agents

Important Practical Considerations

1. Always test susceptibility to all four novel agents - activity is not universal and cross-resistance between ceftolozane-tazobactam and ceftazidime-avibactam can occur (similar mechanisms of action).
2. Meropenem-vaborbactam is NOT useful for DTR-PA - vaborbactam only marginally restores meropenem activity and there are no validated CLSI/FDA breakpoints for this combination against PA.
3. Combination therapy (e.g., novel agent + aminoglycoside) may be considered for severe infections or shock, but combination does not have proven superiority over monotherapy with a novel agent.
4. Phage therapy is experimental - sporadic case reports show success for XDR/DTR-PA but remains investigational. - Sherris Medical Microbiology, p. 3324
5. Resistance to novel agents is emerging - a 2025 review (PMID: 40120758) highlights rapidly emerging resistance mechanisms to newer beta-lactams in PA, underscoring the need for antibiotic stewardship.

Summary Algorithm

DTR P. aeruginosa confirmed
        |
        ├── Test susceptibility to: ceftolozane-TAZ, ceftazidime-AVI, 
        │   imipenem-relebactam, cefiderocol
        |
        ├── Non-MBL DTR-PA:
        │       Preferred: Ceftolozane-TAZ OR Ceftazidime-AVI OR IPM-relebactam
        │       (monotherapy; extended infusion)
        │       Alternative: Cefiderocol
        |
        └── MBL-producing DTR-PA (blaVIM/IMP/NDM confirmed):
                Preferred: Cefiderocol
                + ID specialist consultation mandatory

IDSA 2024 Guidance (current as of December 31, 2023): Infectious disease specialist consultation is recommended for all DTR P. aeruginosa infections. PMID: 39108079